Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Aug;38(8):1834–1837. doi: 10.1128/aac.38.8.1834

Albendazole inhibits Pneumocystis carinii proliferation in inoculated immunosuppressed mice.

M S Bartlett 1, T D Edlind 1, C H Lee 1, R Dean 1, S F Queener 1, M M Shaw 1, J W Smith 1
PMCID: PMC284645  PMID: 7986016

Abstract

Albendazole, a benzimidazole derivative widely used for treating helminth infections, was successfully used to treat and prevent development of Pneumocystis carinii pneumonia in transtracheally inoculated immunosuppressed mice. For treatment, 3 weeks postinoculation, albendazole at 300 and 600 mg/kg of body weight per day was administered in food for 3 weeks. For prophylaxis, albendazole was begun on the same day as inoculation at 300 mg/kg/day for 7 days, and then the dose was reduced to 150 mg/kg/day for 35 additional days. With these regimens, albendazole was effective both for treatment and prophylaxis. Both dexamethasone-immunosuppressed and L3T4+ monoclonal antibody-immunosuppressed mouse models were used, and albendazole inhibited P. carinii infection in both.

Full text

PDF
1837

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett M. S., Edlind T. D., Durkin M. M., Shaw M. M., Queener S. F., Smith J. W. Antimicrotubule benzimidazoles inhibit in vitro growth of Pneumocystis carinii. Antimicrob Agents Chemother. 1992 Apr;36(4):779–782. doi: 10.1128/aac.36.4.779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bartlett M. S., Queener S. F., Durkin M. M., Shaw M. A., Smith J. W. Inoculated mouse model of Pneumocystis carinii infection. Diagn Microbiol Infect Dis. 1992 Feb;15(2):129–134. doi: 10.1016/0732-8893(92)90036-s. [DOI] [PubMed] [Google Scholar]
  3. Blanshard C., Ellis D. S., Tovey D. G., Dowell S., Gazzard B. G. Treatment of intestinal microsporidiosis with albendazole in patients with AIDS. AIDS. 1992 Mar;6(3):311–313. doi: 10.1097/00002030-199203000-00009. [DOI] [PubMed] [Google Scholar]
  4. Chanthavanich P., Nontasut P., Prarinyanuparp V., Sa-Nguankiat S. Repeated doses of albendazole against strongyloidiasis in Thai children. Southeast Asian J Trop Med Public Health. 1989 Jun;20(2):221–226. [PubMed] [Google Scholar]
  5. Cline B. L., Little M. D., Bartholomew R. K., Halsey N. A. Larvicidal activity of albendazole against Necator americanus in human volunteers. Am J Trop Med Hyg. 1984 May;33(3):387–394. doi: 10.4269/ajtmh.1984.33.387. [DOI] [PubMed] [Google Scholar]
  6. Cruz M. C., Bartlett M. S., Edlind T. D. In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles. Antimicrob Agents Chemother. 1994 Feb;38(2):378–380. doi: 10.1128/aac.38.2.378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Di Rosa S., Affronti M., Malta R., Scardavi M., Vassallo L., Occhino C., Maggio A., Savalli F., Rini G. B. The treatment of giardiasis with albendazole. J Chemother. 1989 Jul;1(4 Suppl):948–948. [PubMed] [Google Scholar]
  8. Dieterich D. T., Lew E. A., Kotler D. P., Poles M. A., Orenstein J. M. Treatment with albendazole for intestinal disease due to Enterocytozoon bieneusi in patients with AIDS. J Infect Dis. 1994 Jan;169(1):178–183. doi: 10.1093/infdis/169.1.178. [DOI] [PubMed] [Google Scholar]
  9. Durkin M. M., Bartlett M. S., Queener S. F., Shaw M. M., Lee C. H., Smith J. W. An enzyme-linked immunosorbent assay for enumeration of Pneumocystis carinii in vitro and in vivo. J Clin Microbiol. 1992 Dec;30(12):3258–3262. doi: 10.1128/jcm.30.12.3258-3262.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Edlind T. D., Hang T. L., Chakraborty P. R. Activity of the anthelmintic benzimidazoles against Giardia lamblia in vitro. J Infect Dis. 1990 Dec;162(6):1408–1411. doi: 10.1093/infdis/162.6.1408. [DOI] [PubMed] [Google Scholar]
  11. Horton R. J. Chemotherapy of Echinococcus infection in man with albendazole. Trans R Soc Trop Med Hyg. 1989 Jan-Feb;83(1):97–102. doi: 10.1016/0035-9203(89)90724-4. [DOI] [PubMed] [Google Scholar]
  12. Maisonneuve H., Rossignol J. F., Addo A., Mojon M. Ovicidal effects of albendazole in human ascariasis, ancylostomiasis and trichuriasis. Ann Trop Med Parasitol. 1985 Feb;79(1):79–82. doi: 10.1080/00034983.1985.11811890. [DOI] [PubMed] [Google Scholar]
  13. Morris D. L., Dykes P. W., Dickson B., Marriner S. E., Bogan J. A., Burrows F. G. Albendazole in hydatid disease. Br Med J (Clin Res Ed) 1983 Jan 8;286(6359):103–104. doi: 10.1136/bmj.286.6359.103-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Reynoldson J. A., Thompson R. C., Horton R. J. Albendazole as a future antigiardial agent. Parasitol Today. 1992 Dec;8(12):412–414. doi: 10.1016/0169-4758(92)90193-6. [DOI] [PubMed] [Google Scholar]
  15. Saimot A. G., Meulemans A., Cremieux A. C., Giovanangeli M. D., Hay J. M., Delaitre B., Coulaud J. P. Albendazole as a potential treatment for human hydatidosis. Lancet. 1983 Sep 17;2(8351):652–656. doi: 10.1016/s0140-6736(83)92533-3. [DOI] [PubMed] [Google Scholar]
  16. Sotelo J., del Brutto O. H., Penagos P., Escobedo F., Torres B., Rodriguez-Carbajal J., Rubio-Donnadieu F. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol. 1990 Apr;237(2):69–72. doi: 10.1007/BF00314663. [DOI] [PubMed] [Google Scholar]
  17. Walzer P. D., Foy J., Steele P., Kim C. K., White M., Klein R. S., Otter B. A., Allegra C. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1992 Sep;36(9):1935–1942. doi: 10.1128/aac.36.9.1935. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES